The Walden Group, Inc. is pleased to announce that Arlington Capital Partners has acquired a majority interest in its client, Riverpoint Medical, LLC. Riverpoint is a major developer and manufacturer of advanced bioabsorbable and non-absorbable sutures; high-strength fiber implantables for sports medicine surgery; patented cordless surgeon headlights; and brachytherapy (cancer) devices.
Walden was engaged as Riverpoint’s M&A advisor and helped navigate a careful process to find the best fit for Riverpoint and its principals, the Ferguson family. The process took considerable thought and preparation to pull together a significant amount of information to make sure Riverpoint’s differentiators and R&D and new customer opportunities were clearly understood by prospective partners.
With sophisticated operations based in the United States, substantial customer relationships and unrelenting quality standards, Riverpoint involves immense growth opportunities in multiple healthcare sectors worldwide.
Riverpoint develops and markets innovative products into orthopedic, spine, neuro, cardio-vascular, women’s health and other surgical markets. It is also a major provider of suture-based products for veterinary and dental markets. Its products are sold internationally on a branded, private label and OEM basis and major medtech companies rely on Riverpoint for its innovative offerings to serve patients undergoing critical-care procedures.
About The Walden Group
The Walden Group is a healthcare mergers & acquisition advisory firm. We represent privately-owned companies seeking to divest operations or find a home within an appropriate strategic or private equity firm. We also represent operating companies and financial sponsors seeking to make corporate acquisitions and investments in the healthcare sector. Our approach is "full-immersion", with more than 25 years of healthcare experience, deep industry knowledge, a worldwide network of close relationships and a lengthy track record of completed transactions.
About Riverpoint Medical
Headquartered in Portland, Oregon, Riverpoint Medical is a leading US-based developer, designer, and manufacturer of medical devices focused on advanced bio-medical textile technologies. Riverpoint’s wound closure products include a broad portfolio of high-quality bio-absorbable and non-absorbable sutures for the surgical and animal health markets. The Company’s robust sports medicine offerings include implants and high strength fiber solutions utilizing its proprietary ultra-high molecular weight polyethylene (UHMWPE) non-absorbable suture (HS Fiber®). Additionally, Riverpoint is a leading provider of cordless LED surgical headlights (MedLED®) and offers a suite of brachytherapy products for the oncology market.
About Arlington Capital Partners
Arlington Capital Partners is a Washington, DC-based private equity firm that is currently investing out of Arlington Capital Partners V, L.P., a $1.7 billion fund. Arlington is focused on middle market investment opportunities in growth industries including healthcare, government services and technology, aerospace & defense, and business services and software. The firm’s professionals and network have a unique combination of operating and private equity experience that enable Arlington to be a value-added investor. Arlington invests in companies in partnership with high quality management teams that are motivated to establish and/or advance their Company’s position as leading competitors in their field.